Small cap round up

Surveillance, security and safety visual intelligence company Digital Barriers posted an update on trading for the six months to 30 September on Wednesday, and also announced the award of a contract with a US government agency to begin implementing its ThruVis technology for public transport security.The AIM-traded firm said overall group revenue for the half-year, which includes a full contribution from Brimtek as acquired on 1 March, is expected to be approximately double that achieved in the same period last year.

Bonding solutions and adhesives company Scapa Group posted a period-end update for the six months to 30 September on Wednesday.The AIM-traded firm said group revenue, trading profits and margins were all ahead of last year.

Following on from success with a similar venture in Portugal, magazine publisher Time Out is to open a market in Shoreditch, east London to show off its skills in identifying the best cuisine, cocktails and cultural experiences.The AIM-listed group has signed a conditional lease for a new market at 106 Commercial Street, subject to planning permission, following on from its flagship market which opened in Lisbon in May - and with plans in the pipeline for similar markets in New York and Miami.

Stobart Group has won a one-year contract with the UK Environment Agency to provide incident response logistics services in areas threatened with flooding. Stobart's rail arm, which will manage the contract using logistics expertise from across the group, assist with logistics, storage and transport requirements.

Botswana and southern Africa-focused coal bed methane developer Tlou Energy announced on Wednesday that it has received an initial Independent Reserve Certification from SRK Consulting, for the Lesedi CBM Project located in prospecting licence PL002/2004 in Botswana.“I am absolutely delighted with this news; it is a very significant achievement for Tlou,” said chief executive of the AIM and ASX-traded firm, Gabaake Gabaake.

AIM-listed regenerative medical devices company Tissue Regenix Group’s saw operating losses widen at the interim stage even as its revenues nudged higher, although it did gain regulatory approval for its products in Europe and the US. For the six months ended 31 July, revenue increased by 150% to £631,000 when compared to the same period the previous year, while its operating losses widened by about 34% to £5.52m in line with its expectations.